Pharmacy benefit manager shares dropped sharply Wednesday as lawmakers introduced bipartisan legislation requiring health insurers and PBMs to divest pharmacy operations within three years. The proposal intensifies scrutiny of the PBM industry's influence over drug pricing.
Bipartisan Bill Targets Vertical Integration in Healthcare
According to Reuters, following the presentation of a bipartisan measure on Wednesday, which would compel health insurers or drug intermediaries to sell off their pharmacy businesses, shares of companies owning pharmacy benefit managers declined.
The majority of pharmacy benefit management (PBM) in the US is controlled by CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum. All three of these parent firms also own health insurance businesses.
Following the initial reporting of the bill in the Wall Street Journal, all three firms' shares fell by 4.8% to 5.5%.
The bill, which is being co-sponsored by Republican Josh Hawley and Democratic Elizabeth Warren in the United States Senate, would require, within three years, that companies that own health insurers or pharmacy benefit managers sell their shares in pharmacies.
Healthcare Stocks React to Bipartisan Proposal
This bill will be submitted in Congress with the support of Republican Diana Harshbarger and Democratic Jake Auchincloss.
Pharmacy benefit managers (PBMs) mediate pricing negotiations for prescription prescriptions between insurance companies, pharmacies, and pharmaceutical companies. PBMs then pay pharmacies directly for the medications covered by their contracts.
They have already been investigated for the impact they have on the cost of prescription drugs.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business. My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen," Senator Warren stated.
Other Insurers Feel the Ripple Effect of PBM Legislation
Other insurance companies' stock prices dropped 1% to 3%. This included Centene, Elevance, and Humana, Investing.com shares.
"The latest introduction of potential legislation to restrict PBM operations and broader healthcare vertical integration is unlikely to gain traction, although it is hard to dismiss outright," Michael Cherny, an analyst at Leerink Partners, said.
Insurance company stock has taken a beating following last week's shooting death of UnitedHealth health insurance unit CEO Brian Thompson outside a Manhattan hotel.


AI Memory Boom Sparks Global Chip Supply Crunch
Wall Street Rallies as SpaceX IPO Soars and U.S.-Iran Peace Deal Hopes Grow
European Stocks Rise Ahead of ECB Rate Decision as Investors Buy the Dip
Asics Considers Onitsuka Tiger Spinoff as Luxury Sneaker Brand Expands Globally
ECB Set to Raise Interest Rates as Energy Shock Fuels Eurozone Inflation Concerns
Russia Stocks End at Six-Month Low as MOEX Index Stalls, Gold Surges and Oil Retreats
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement
IMF Advances Ukraine Loan Program, Clears $690M Disbursement
Adobe Beats Q2 2026 Estimates, Raises Full-Year Outlook as AI Revenue Surges Despite Stock Drop
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027
Meta AI Strategy Faces Challenges as Zuckerberg Admits Mistakes in Internal Memo
Oil Prices Fall as Trump Signals Iran Deal, Reducing Supply Risk Concerns
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal
US Dollar Heads for Weekly Loss as Iran Peace Deal Hopes Boost Risk Appetite
DOJ Clears Paramount Skydance-Warner Bros. Discovery Merger Without Conditions 



